World Biosimilar Congress 2017

TRACK 1   

World Biosimilar Congress 2017

     TRACK 2 

*New* Track 1: Market access strategies, opportunities and commercial challenges 

  • Updates on biosimilar and biobetter regulatory guidelines
  • Streamlining approval and access for follow-on biologics
  • Opportunities and challenges in bringing future  biosimilars to market
  • Emerging markets and the establishment of biosimilar products
  • Technology transfer strategies for market access
  • Successful biosimilar product case studies from benchtop to market‚Äč

‚ÄčTrack 2: Biosimilar and Biobetter Development

  • Biosimilar and biobetter development and clinical case studies
  • Designing and conducting global clinical trials
  • Designing clinical models and using data to effectively demonstrate biosimilarity
  • Opportunities in biobetters development
  • The latest on demonstrating interchangeability
  • Approaches to harmonizing immunogenicity testing
  • Novel techniques and technologies for characterisation, assay development and extrapolation
  • *New* Pharmacovigilence (side effects) and innovative clinical trials 

conference presentation biosimilar day 1

Biosimilar panel discussion

biosimilar conference speaker




Adam Levysohn , Sr Director Market Access Biosimilar, Biogen 
Anne Cook , Quality Assessor, MHRA
Benedicte Lunddahl , Head of Pharmacovigilance, Danish Medicines Agency 
Ber Oomen , Executive Secretary, European Specialist Nurses Organisations
Caroline Boulliat , Immunology, Oncology, Biosimilar Business Unit Head, Amgen Europe
Dan Cimpoeru , Board Member, European Cancer Patient Coalition (ECPC)
Elena Wolff-Holz , Chair, Biosimilar Medicinal Products Working Party (BMWP) of EMA
Erin Federman , Global Director, Team Lead, Immunology Biosimilars, Boehringer Ingleheim 
Francois Xavier Frapaise , Vice President, Clinical Development, Drug Safety & Medical Affairs, Merck Biosimilars
Ian Henshaw , Global Head of Business Operations and Alliance Management, Biogen
Ingrid Schwarzenberger , Head Global Regulatory Affairs, Sandoz Biopharmaceuticals 
Margaret Dolan , Specialist Procurement Pharmacist, Procurement Team, NHS Commercial Solutions

2017 Speakers:  
Andrew J. G. Simpson , Scientific Director, Orygen Biotecnologia 
Andrew Spiegel
, Executive Director, Global Colon Cancer Assn.
Anjan Selz
, Vice President – Head of Biosimilars EMEA, Lupin Europe Ltd
Alain Beck
, Senior Director Analytical Chemistry, CIPF and Associate Editor, mAbs 
Caroline Boulliat
, Immunology, Oncology, Biosimilar Business Unit Head, Amgen Europe
Catherine Evans
, Strategic Marketing and Business Development for Biopharmaceutical Applications, Bruker Daltronik
Cecil Nick
, Vice President, Biotechnology, PAREXEL
Dipak Thakur
, General Manager, Genomics and Biotechnology, Wockhardt Ltd
Divya Chadha Manek
, Head of Commercial Business Development and Marketing, NIHR Clinical Research Network (NIHR CRN) 
Eduardo Cruz
, CEO, Axis Biotec
Florian Turk
, Head Global Payor Marketing, Sales and Relations, Sandoz Biopharmaceuticals
George Stefanov
, Hospital & Biologics Marketing Operations Director, Europe, Mylan
Gianluca Trifirò
, Department of Biomedical Sciences, Dentistry and Morphological and Functional Images, University of Messina – Italy
Joanna Brougher
, Biotech, Pharma and Medical Device IP and Corporate Counsel; Adjunct Lecturer, Harvard School of Public Health
Joaquín Rodrigo
, Director General, Sandoz Pharmaceuticals Spain
Huiguo Hu (Forrest Hu)
, General Manager, International Business, 3S PHARMACEUTICAL GROUP
Karsten Roth
, Director Clinical Operations, Cinfa Biotech
Mathias Flume
, Head of Drug Department, KVWL
Michael Reilly
, Executive Director, Alliance for Safe Biologic Medicines  
Nicholas Cappuccino
, Vice-President, Head of Quality and Scientific Affairs, Dr Reddy's Laboratories
Patrick Liu
, Vice President of Global Biologics R&D and Head of Biologics, Assays and Technology, Teva USA
Jonathan Underhill
, Associate Director for Medicines Evidence, NICE 
Peter Jørgensen
, CEO, Danish Generic and Biosimilar Medicines Industry Association (IGL) 
Pieter Dylst
, Senior Manager Market Access, Biosimilar Medicines Group
René Wuttke
, Bioanalytical Principal Investigator, Global Bioanalytical Services, Celerion
Richard DiCicco
, Chairman, Harvest Moon Pharmaceuticals
Ruediger Jankowsky
, Managing Director, Cinfa Biotech GmbH
Salomon Stavchansky
, ‎Alcon Centennial Professor of Pharmaceutics, University of Texas
Steinar Madsen
, Medical Director, Norwegian Medicines Agency
Tarek Kilani
, Former Head of Pharmacy & Continuing Medical Education Coordinator, Emirates French Hospital
Tim Shea
, Director, Sterne, Kessler, Goldstein & Fox
Tudor Arvinte
, Owner, Therapeomic Inc.
Uwe Gudat
, Head of Safety, Biosimilars, Merck
Victor Lino Mendonça
, Head of Policy & Market Access Europe, Mylan
William Christopher Lamanna
, ‎Global Scientific Affairs Manager, Sandoz




Get involved

To sponsor or exhibit contact Derek Cavanagh on +44 (0) 207 0921 297
or email  derek.cavanagh@terrapinn.com